NextCell Pharma AB ("NextCell") announces that Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma AB, has been elected Vice President Elect for Europe within the International Society for Cell and Gene Therapy (ISCT). The role is a key position within the organisation’s global leadership, offering significant influence over the future direction of cell and gene therapies, both across Europe and internationally.
As VP Elect, Dr Davies will play an active role in driving strategic initiatives across the European cell and gene therapy community. Her focus will include promoting regional expertise and fostering collaboration between academia, clinicians, industry and regulators. The position also grants her a seat on ISCT’s global leadership team, where she will contribute to shaping international standards, policies and long-term priorities for the field.
Her two-year term as VP Elect begins at the ISCT Annual Meeting in New Orleans in May 2025, after which she will assume the role of Vice President for Europe, taking on full leadership responsibility for the region.
Dr Davies brings a wealth of experience to the role, having served as Secretary for Europe and as the inaugural Chair of ISCT’s European Industry Committee. With a career spanning both academic research and the biotech sector, she has consistently bridged the gap between scientific discovery and clinical impact—an approach that defines her work at NextCell and now stands to benefit ISCT at large.
“I am proud and honoured to have been entrusted with this role by ISCT’s European members. It is a fantastic opportunity to support the advancement of translational medicine in cell and gene therapy, and to help elevate Europe’s contribution globally,” said Dr Davies.
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.